Geburtshilfe Frauenheilkd 2018; 78(10): 191
DOI: 10.1055/s-0038-1671332
Poster
Freitag, 02.11.2018
Gynäkologische Onkologie IV
Georg Thieme Verlag KG Stuttgart · New York

Significant overall survival improvement in proliferative subtype ovarian cancer patients receiving bevacizumab

S Kommoss
1   Department für Frauengesundheit, Universitätsklinikum Tübingen, Tübingen, Deutschland
,
F Heitz
2   Kliniken Essen-Mitte (KEM), Gynäkologie und Gynäkologische Onkologie, Essen, Deutschland
,
B Winterhoff
3   University of Minnesota, Division of Gynecologic Oncology, Minneapolis, Vereinigte Staaten von Amerika
,
C Wang
4   Mayo Clinic, Rochester, Vereinigte Staaten von Amerika
,
U Canzler
5   Uni.-Klinikum Carl Gustav Carus, Dresden, Deutschland
,
C Aliferis
6   Academic Health Center, University of Minnesota, Institute for Health Informatics (IHI), Minneapolis, Vereinigte Staaten von Amerika
,
A Belau
7   Universitätsmedizin Greifswald, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Greifswald, Deutschland
,
J Wang
6   Academic Health Center, University of Minnesota, Institute for Health Informatics (IHI), Minneapolis, Vereinigte Staaten von Amerika
,
L Hanker
8   Universitätsklinikum Schleswig-Holstein Campus Lübeck, Klinik für Frauenheilkunde und Geburtshilfe, Lübeck, Deutschland
,
F Kommoss
9   Institut für Pathologie im Medizin Campus Bodensee Friedrichshafen, Friedrichshafen, Deutschland
,
A du Bois
2   Kliniken Essen-Mitte (KEM), Gynäkologie und Gynäkologische Onkologie, Essen, Deutschland
,
S Ma
6   Academic Health Center, University of Minnesota, Institute for Health Informatics (IHI), Minneapolis, Vereinigte Staaten von Amerika
,
J Sehouli
10   Universitätsmedizin Berlin Charité, Campus Virchow Klinikum, Klinik für Frauenheilkunde, Berlin, Deutschland
,
R Kimmig
11   Universitätsklinikum Essen, Frauenklinik, Essen, Deutschland
,
R Tourani
6   Academic Health Center, University of Minnesota, Institute for Health Informatics (IHI), Minneapolis, Vereinigte Staaten von Amerika
,
C Kurzeder
12   Universitätsspital Basel, Frauenklinik, Basel, Schweiz
,
S Mahner
13   Klinikum der Ludwig-Maximilians-Universität München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, München, Deutschland
,
TW Park-Simon
14   Medizinische Hochschule Hannover, Gynäkologische Onkologie, Hannover, Deutschland
,
SC Dowdy
4   Mayo Clinic, Rochester, Vereinigte Staaten von Amerika
,
J Pfisterer
15   Zentrum für Gynäkologische Onkologie Kiel, Kiel, Deutschland
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
20. September 2018 (online)

Auch verfügbar auf
 

Background:

We previously demonstrated that bevacizumab may differentially improve ovarian cancer progression-free survival (PFS) depending on TCGA molecular subtypes. Despite recent progress in the molecular biology of epithelial ovarian cancer, results have not yet translated into individualized treatment options. In the current study we correlated mature overall survival data with TCGA subtypes in ovarian cancer patients from the AGO-OVAR11 trial.

Experimental Design:

Whole genome DASL gene expression arrays were performed on FFPE tissues from the AGO OVAR11 trial. Patients were stratified into four TCGA molecular subtypes. Correlation between molecular subtype and the efficacy of randomly assigned therapy with bevacizumab was assessed.

Results:

Among all four TCGA suptypes, only patients with tumors of the proliferative subtype had a statistically significant benefit from the addition of bevacizumab to standard chemotherapy. Median PFS and OS of proliferative subtype patients was 22.17 and 52.43 months respectively if bevacizumab was added to standard chemotherapy but only 12.0 and 35.27 months in the control arm. Anti-angiogenic therapy resulted in a median PFS improvement of 10.2 months (HR 0.48, p = 0.002) and in a median improvement of overall survival (OS) of 17.2 months (HR 0.54, p = 0.021) among TCGA proliferative subtype patients. The remaining three non-proliferative subtypes showed no statistically significant improvement of PFS or OS after addition of bevacizumab.

Conclusions:

We demonstrate for the first time significant OS benefit in patients with TCGA proliferative molecular subtype. Our findings may help to develop molecularly stratified treatment strategies and hold potential to ultimately improve outcome in patients with ovarian cancer.